An analysis on distribution and inter-relationships of biomarkers under edoxaban in Japanese patients with non-valvular atrial fibrillatio
- Conditions
- Patients with non-valvular atrial fibrillation who are taking edoxaban for prevention of ischemic stroke
- Registration Number
- JPRN-UMIN000028383
- Lead Sponsor
- Medical Science Department Daiichi-Sankyo Co. LTD.
- Brief Summary
1) PC-Ed by LC-MS/MS was 194.3 (49.4-345.3) and 17.0 (4.8-40.7) ng/mL at peak and trough. 2) Correlation of PT with PC-Ed was higher than that of aPTT. 3) Among 6 PT reagents, Coagupia PT-N and Simplastin Excel S (both PT reagents) showed the highest predictive capability for the upper outlier of PC-Ed at peak and trough.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 106
Not provided
(1) Receiving dual anti-platelet therapy (2) Inadequate dosage of edoxaban at registration (3) Edoxaban hypersensitivity (4) Patients who are bleeding (5) Patients with acute bacterial endocarditis (6) Renal dysfunction (creatinine clearance <30 mL/min) (7) River dysfunction with clotting disorder (8) Patients who had admitted with cardiovascular disease (stroke, myocardial infarction, PCI, and heart failure) or bleeding requiring hospitalization within 1 month before the registration (9) Patients who did not give written informed consents for this study (10) Patients who are judged by the researchers as inadequate for this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method